The targeting S1P metabolism is ongoing with a humanized version of that anti-S1P mAb, which is being investigated as a treatment for metastatic ccRCC in patients that have failed up to three targeted therapies (www.lpath.com). This evidence concerns the gene MBTPS1 and nonpapillary renal cell carcinoma.